Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total

Executive Summary

FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year, according to an analysis by F-D-C Reports' Pharmaceutical Approvals Monthly
Advertisement

Related Content

MGI Aloxi Launch Set For September; Indications Include Delayed Nausea
MGI Aloxi Launch Set For September; Indications Include Delayed Nausea
Bexxar Retreatment, Leukemia Reports Among Corixa’s Phase IV Studies
CBER Reviewers To Remain Accessible Post-Merger, CDER Tells BLA Sponsors
CBER Reviewers To Remain Accessible Post-Merger, CDER Tells BLA Sponsors
FDA Multi-Cycle Product Review Analysis To Begin In Fiscal 2004
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
Approval Delays For Standard NMEs Caused Primarily By “Safety Issues” – FDA
FDA Approval Is “First Action” For 32% Of NMEs; Rate Less Than Other NDAs
NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002
Advertisement
UsernamePublicRestriction

Register

PS042190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel